PISCATAWAY, N.J., April 22 Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced the appointment of Dale Johnson as Director of International Distribution, responsible for overseeing the Company's network of independent dental distributors operating in the European Union.
Currently, Milestone's EU distribution network is comprised of leading dental supply companies serving dental professionals throughout Europe - all of which are engaged in the active sales and marketing of Milestone's Computer-Controlled Local Anesthesia Delivery systems, including the STA Single Tooth Anesthesia System(TM) (STA System), The Wand® and CompuDent®, as well as all related disposable handpieces. Reporting directly to Milestone's Chief Executive Officer, Leonard Osser, Johnson is charged with supporting and enhancing customer relationships, promoting greater sales growth and winning new distribution agreements with other major suppliers in this global region.
According the 2009 Dental Market Report released by the Association of Dental Dealers in Europe, the number of practicing dentists in Europe is 268,000, representing a sizable portion of the global dental equipment and consumables market that is estimated by research firm Markets and Markets to grow to $26 billion by 2014.
"We are very pleased to welcome Dale to Milestone's management team. His proven knowledge and experience in building and managing global distribution networks should prove invaluable to our Company," stated Osser.
A 25-year veteran of the pharmaceutical industry, Johnson joins Milestone after serving first as Director of Marketing and then Vice President, International Business at Zila Pharmaceuticals, Inc., a leader in the prevention and treatment of oral diseases. While at Zila, he was instrumental in building a worldwide distribution network for Zila's products, which included Vizilite Plus and Peridex; and was responsible for the development of key marketing strategies to get dental professionals to screen for oral cancer utilizing Zila's proprietary technology with a goal of identifying oral cancer in the early stage. Johnson's prior executive posts also included Executive Vice President at MedLearning, a communications company serving the pharmaceutical and biotech industries; Group Vice President of Business Development at DOBI Medical Systems, Inc., a technology company engaged in the diagnosis of breast cancer; and Executive Vice President at Apex Communications, Inc., a medical communications company providing marketing and communications support to a blue chip customer base that included Pfizer, GlaxoWellcome, AstraZeneca, and SmithKline Beecham, among many more. From 1984 through 1995, Johnson rose through the ranks at Glaxo, Inc., beginning first as a sales executive and ascending to International Marketing Director for Dermatology Products. He began his professional career working for Pfizer, Inc. as a Medical Service Representative.
Johnson is a graduate of Brigham Young University, where he received a Bachelor of Arts degree in Organizational Communication. He also earned both a Masters degree in Human Resources Development and an MBA from Webster University-San Antonio.
About Milestone Scientific Inc.
Headquartered in Piscataway, New Jersey, Milestone Scientific is engaged in pioneering advanced computer-controlled injection technologies for the medical and dental markets; and currently sells its award-winning products through a global distribution network serving North America, Asia, Africa and Europe. For more information on the STA System(TM) and other innovative Milestone products, please visit the Company's web sites found at www.milestonescientific.com and www.STAis4U.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2009. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
FOR MORE INFORMATION, PLEASE CONTACT: Elite Financial Communications Group Dodi Handy, President and CEO (Twitter: @dodihandy) For Media Inquiries: Kathy Addison, Director, Elite Media Group (Twitter: @kathyaddison) 407-585-1080 or via email at [email protected]
SOURCE Milestone Scientific Inc.